On Thursday, Gulfport Energy Corporation (NASDAQ:GPOR)’s shares inclined 5.84% to $34.05.
Gulfport Energy Corporation (GPOR) stated financial and operational results for the quarter ended June 30, 2015 and offered an update on its 2015 activities. Key information for the second quarter comprises the following:
- Net production averaged 473.9 MMcfe per day, an enhance of 196% contrast to the second quarter of 2014 and an enhance of 12% as contrast to the first quarter of 2015.
- Estimated July 2015 net production averaged 574 MMcfe per day, a 21% enhance over the second quarter of 2015.
- Realized natural gas price before the impact of derivatives and counting transportation costs averaged $2.23 per Mcf, a $0.41 per Mcf differential to NYMEX during the quarter.
- Net loss of $31.3 million, or $0.32 per diluted share.
- Adjusted net income of $250,000, or $0.00 per diluted share.
- Adjusted EBITDA of $84.6 million.
- Raised 2015 full-year production guidance to a range of 517 MMcfe per day to 541 MMcfe per day, an enhance of 115% to 125% over 2014 average daily production.
Gulfport Energy Corporation engages in the acquisition, exploration, exploitation, and production of natural gas, natural gas liquids (NGLs), and crude oil in the United States. The company’s principal properties are located in the Utica Shale primarily in Eastern Ohio; Louisiana Gulf Coast in the West Cote Blanche Bay; and Hackberry fields.
Avon Products, Inc. (NYSE:AVP)’s shares dropped -0.33% to $6.00.
Avon Products, Inc. (AVP) stated second-quarter 2015 results. “Our overall second-quarter performance was in line with our expectations in an environment of extraordinary currency pressure. Market by market, our local teams are operating effectively as they address consumer demands, improve Representative engagement and manage cost,” said Sheri McCoy, Chief Executive Officer of Avon Products, Inc. “In addition, given that we anticipate the challenging environment to continue, we have taken steps to improve our financial flexibility.”
Second-Quarter 2015 Income Statement Review (contrast with second-quarter 2014)
- Total revenuefor Avon Products, Inc. reduced 17% to $1.8 billion, but was relatively unchanged in constant dollars. Constant-dollar revenue benefited from growth in Europe, Middle East & Africa, in addition to Latin America, due to markets experiencing high inflation (Venezuela and Argentina), partially offset by a decline in North America.
- Active Representatives were down 2% year over year, led by a continued decline in North America, partially offset by growth in Europe, Middle East & Africa, most significantly Russia. Average order raised 2%, which benefited from price enhances in markets experiencing high inflation.
- Total units reduced 4%, driven by declines in Latin America and North America. Price/mix was up 4% during the quarter, aided by pricing in markets experiencing high inflation in addition to improved price/mix in Brazil.
Avon Products, Inc. manufactures and markets beauty and related products worldwide. It offers beauty products, such as skincare, and personal care products, in addition to fragrances and color cosmetics; and fashion and home products comprising of jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products, and nutritional products.
At the end of Thursday’s trade, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)‘s shares surged 1.49% to $10.88.
Ironwood Pharmaceuticals, Inc. (IRWD) offered an update on its second quarter 2015 and recent business activities.
LINZESS® (linaclotide)
- LINZESS U.S. net sales, as offered by Allergan plc, were $112.1 million in the second quarter of 2015, an about 79% enhance contrast to the second quarter of 2014.
- More than 510,000 total LINZESS prescriptions were filled in the second quarter of 2015, an about 56% enhance contrast to the second quarter of 2014, and nearly three million LINZESS prescriptions have been filled since the product’s launch in December 2012, according to IMS Health.
- Net profit for the LINZESS brand partnershipin the U.S., counting commercial costs and expenses and research and development (R&D) expenses, was $15.0 million in the second quarter of 2015. LINZESS U.S. net profit is shared equally with Allergan.
- About 140,000 healthcare practitioners have prescribed LINZESS to more than 760,000 unique patients since the product’s launch, according to IMS Health.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnership agreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.
Key Energy Services, Inc. (NYSE:KEG), ended its Thursday’s trading session with 0.75% gain, and closed at $0.860.
Key Energy Services, Inc. (KEG) stated second quarter 2015 merged revenues of $197.5 million and a pre-tax GAAP loss of $96.1 million, or $0.42 per share. The results for the second quarter comprise:
- a pre-tax loss of $21.4 million, or $0.10 per share, related to a pending sale and the associated impairment of our assets in Oman;
- pre-tax costs of $8.4 million, or $0.04 per share, related to the formerly revealed Foreign Corrupt Practices Act (“FCPA”) investigations;
- a pre-tax loss of $2.1 million, or $0.01 per share, on the sale of certain U.S. assets; and
- pre-tax costs of $1.1 million due to severance.
Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
